Phosphoglycerate dehydrogenase (PHGDH) is a suitable marker for risk stratification, as it is highly upregulated in high-risk MYCN-amplified neuroblastoma; however, its inhibition by small molecule inhibitors antagonized chemotherapy efficiency in patient-derived xenografts in mice [23]. Here, MYCN is linked to neuroblastoma.